Novartis expects China to play key role in its global development plans and drug research program. For Joseph Jimenez, chief executive officer of Novartis AG, making a visit to China is an opportunity to seek ways to participate in the country’s ongoing economic transition and shape the multinational pharmaceutical corporation’s future strategy. China is contributing an increasing share to Novartis’ global business. “Five years ago, China was in the top 20. Now it is in the top 10, and in five years, it is going to be in the top three,” Jimenez said. In particular, Jimenez said, the Novartis Shanghai research and development center, officially named as Novartis Institutes for BioMedical Research (China), which is to complete the first phase of its construction later this year, will serve as a perfect meeting point of the company’s global vision and China’s pledge of a consistent open policy in its economic transition.